99mTc-Annexin A5 uptake and imaging to monitor chemosensitivity.
Most anticancer agents act by inducing apoptosis in sensitive tumor cells. Hence, in many types of cancers, significant increase of tumor apoptosis after chemotherapy correlates with tumor chemosensitivity. Theoretically, a reliable evaluation of apoptotic changes, postchemotherapy to baseline, may provide valuable insights into the apoptotic competence of cancers. Until now, assessment of chemosensitivity has usually relied upon histological evidence of tumor response (i.e., partial or complete disappearance of tumor cells) or demonstration of tumor shrinkage by means of morphological imaging (i.e., computed tomography or magnetic resonance imaging). In clinical practice, however, these conventional methods are proving ineffective for monitoring tumor chemosensitivity on a daily basis. Recent developments in molecular imaging have allowed the synthesis of a new radiolabeled agent, 99mTc-recombinant human Annexin A5, designed to the assessment of apoptotic response of cancers after a single course of chemotherapy. Such in vivo technique opens promising perspectives for evaluating, noninvasively and early, tumor response to anticancer therapies. Alternative methods for Annexin A5 labeling and imaging may improve the detection of drug-induced apoptosis to monitor chemosensitivity.
Belhocine
Tarik Z
TZ
Department of Nuclear Medicine, Jules Bordet Cancer Institute, Brussels, Belgium.
Blankenberg
Francis G
FG
D000818:Animals; D017304:Annexin A5 / Q000493:pharmacokinetics*; D000970:Antineoplastic Agents / Q000493:pharmacokinetics*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017209:Apoptosis; D045744:Cell Line, Tumor; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D051379:Mice; D008956:Models, Chemical; D008958:Models, Molecular; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000188:drug therapy*; D009374:Neoplasms, Experimental / Q000188:drug therapy; D011241:Prednisone / Q000627:therapeutic use; D011487:Protein Conformation; D017433:Protein Structure, Secondary; D011874:Radiometry; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D011994:Recombinant Proteins / Q000737:chemistry; D013667:Technetium / Q000494:pharmacology*; D013997:Time Factors; D015899:Tomography, Emission-Computed, Single-Photon; D014750:Vincristine / Q000627:therapeutic use
D017304:Annexin A5; D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals; D011994:Recombinant Proteins; D014750:Vincristine; D013667:Technetium; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone